Article -> Article Details

Market Overview

The global vaccine market size was valued at USD 59.83 Billion in 2024 and is projected to reach USD 136.46 Billion by 2033, growing at a CAGR of 9.12% during 2025-2033. The market growth is driven by factors such as rising infectious diseases, government vaccination programs, biotechnology advancements including mRNA and recombinant vaccines, and increasing health awareness worldwide. Asia-Pacific currently holds the largest market share, reflecting significant regional development in vaccine production and adoption. 

Study Assumption Years

• Base Year: 2024
• Historical Period: 2019-2024
• Forecast Period: 2025-2033

Vaccine Market Key Takeaways

• The global vaccine market size was valued at USD 59.83 Billion in 2024
• The market is projected to exhibit a CAGR of 9.12% during 2025-2033
• The market forecast period is from 2025 to 2033
• Asia-Pacific dominates the market with over 38.9% share in 2024
• Market growth is driven by infectious disease prevalence, advances in biotechnology, and vaccination awareness
• Government programs and public-private partnerships are expanding vaccine access globally
• Rising health consciousness, especially in developing regions, fuels vaccine adoption

Sample Request Link:

 https://www.imarcgroup.com/vaccine-market/requestsample

Market Growth Factors

The global vaccine market is primarily driven by the escalating incidence of infectious diseases such as seasonal flu, HPV, and emerging viruses like COVID-19. These health challenges elevate the demand for effective immunizations. Strengthened government-led vaccination programs, international health initiatives, and collaborative public-private partnerships are extensively expanding vaccine access and awareness worldwide, further boosting market growth.

Technological progressions notably influence market expansion. Innovations like mRNA and recombinant vaccine platforms have revolutionized vaccine development timelines and effectiveness. The increasing investment by pharmaceutical companies and global health organizations in research and development of both preventive and therapeutic vaccines supports ongoing innovation, driving robust market growth.

Growing health consciousness among populations, coupled with improved healthcare infrastructure in developing regions, is encouraging wider vaccine adoption. The aging population's increasing need for adult immunization also contributes significantly to market expansion. These factors collectively provide a strong impetus for the sustained growth of the global vaccine market.

Market Segmentation

Analysis by Technology:

• Conjugate Vaccines: Highly effective in infants and young children, especially against bacterial infections like Hib and pneumococcus. They enhance immune response by linking weak antigens to strong carrier proteins and are widely used in pediatric immunization programs.
• Inactivated and Subunit Vaccines: Preferred for their safety, stability, and low side effects. Widely used for influenza, hepatitis B, and pertussis. Their compatibility with adjuvants and ease of storage favors global immunization efforts.
• Live Attenuated Vaccines: Extremely effective by mimicking natural infections to stimulate long-lasting immunity. Used in diseases such as measles, mumps, rubella, and varicella. Innovations in oral and nasal delivery improve accessibility.

Analysis by Patient Type:

• Pediatric: Holds around 56.0% market share in 2024. Driven by increasing immunization programs, government initiatives, advancements in vaccine technology, and heightened COVID-19 vaccination efforts for children.

Analysis by Indication:

• Bacterial Diseases: Growth driven by the rising incidence of bacterial infections, including those caused by Streptococcus pneumoniae and Haemophilus influenzae. Advances in vaccine technology have improved effectiveness for bacterial disease immunizations.

Analysis by Route of Administration:

• Intramuscular and Subcutaneous Administration: IM injections facilitate efficient vaccine uptake and strong immune responses. Subcutaneous injections offer slower, sustained release of vaccines and appeal to needle-sensitive individuals.

Analysis by Product Type:

• Multivalent Vaccine: Leading the market with about 66.7% share in 2024. They combine antigens from different pathogens to reduce injections, simplify immunization schedules, and improve efficiency and economics.

Analysis by Treatment Type:

• Preventive Vaccine: Dominates the market with 56.2% share in 2024. Designed to proactively provide immunity by stimulating antibody production, effectively reducing disease incidence and severity.

Analysis by End User:

• Hospitals: Lead the market with 57.3% share in 2024. Hospitals provide critical vaccine storage, distribution, administration, and are trusted sources promoting vaccination awareness.

Analysis by Distribution Channel:

• Hospital Pharmacies: Central to vaccine distribution, ensuring access and adherence to quality controls, collaborating with healthcare providers and government agencies to maintain vaccine efficacy and availability.

Regional Insights

In 2024, Asia-Pacific dominated the vaccine market, accounting for over 38.9% of the global share. The region's growth is propelled by its expanding pharmaceutical and biotechnology sectors, significant government investments in healthcare infrastructure, and manufacturing capacities. Countries like India and China have enhanced vaccine production capabilities and fostered public-private partnerships, promoting innovation and large-scale vaccine accessibility, thereby strengthening Asia Pacific's leadership in the global vaccine market.

Recent Developments & News

In February 2025, IAVI and Biofabri launched the IMAGINE clinical trial of the MTBVAC tuberculosis vaccine across South Africa, Kenya, and Tanzania. December 2024 saw Valneva and Serum Institute of India entering an exclusive license agreement to expand chikungunya vaccine access in Asia, backed by CEPI's USD 41.3 Million funding. July 2024 involved GSK acquiring full licensing rights for mRNA vaccines from CureVac for influenza and COVID-19. In May 2024, Sanofi and Novavax agreed on co-commercialization of a protein-based COVID-19 vaccine and combination flu-COVID-19 vaccines. Moderna advanced multiple late-stage vaccine trials in March 2024, supported by USD 750 Million from Blackstone Life Sciences for flu vaccine development.

Key Players

• Abbott Laboratories
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bharat Biotech International
• Bavarian Nordic A/S
• CSL Limited
• Daiichi Sankyo Company Limited
• Emergent BioSolutions Inc.
• GlaxoSmithKline Plc
• Inovio Pharmaceuticals Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
• Novavax Inc.
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi Pasteur SA (Sanofi SA)
• Serum Institute of India Pvt. Ltd.
• Takeda Pharmaceutical Company Limited.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization:

https://www.imarcgroup.com/request?type=report&id=2374&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302